Perrigo launches its own store-brand Voltaren Arthritis Pain reliefPerrigo has launched the store-brand equivalent of GSK Consumer Healthcare’s Voltaren Arthritis Pain, which has been approved by the Food and Drug Administration. Hikma launches generic VidazaAzacitidine for injection had a market value of approximately $82 million for the 12 months ended July 2020, according to IQVIA. Dr. Reddy's intros store-brand Voltaren Arthritis Pain Dr. Reddy’s is offering over-the-counter diclofenac sodium topical gel 1%, the store brand version of GSK Consumer Healthcare's Voltaren Arthritis Pain Amneal offers generic Axid Amneal is bringing generic Axid, an oral liquid formulation of nizatidine, back to market. Dr. Reddy's debuts generic Faslodex Faslodex and its generic had a market value of approximately $407 million for the most recent 12 months ended June 2020, according to IQVIA. FDA gives Alembic tentative nod for generic Remodulin Remodulin injection had a market value of roughly $466.1 million for the 12 months ended December 2019. Lupin rolls out generic Arava Leflunomide tablets had a market value of roughly $42 million, according to June IQVIA data. FDA grants Zydus Cadila approval for generic ProAmatine Zydus Cadila's generic ProAmatine is approved in dosage strengths of 2.5 mg, 5 mg, and 10 mg. Dr. Reddy's intros generic Concerta The Concerta brand and generic had a market value of roughly $1.2 billion for the most recent 12 months ending June 2020, according to IQVIA. Indoco Remedies obtains FDA OK for generic Zyprexa Olanzapine tablets have a market value of $65 million, according to IQVIA data. First Previous 139 140 141 142 143 Next Last
